查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1538449

前列腺癌抗原 3 检测市场报告：2030 年趋势、预测与竞争分析

Prostate Cancer Antigen 3 Test Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

前列腺癌抗原 3 检测的趋势和预测

预计 2024 年至 2030 年，全球前列腺癌抗原 3 检测市场将以 7.7% 的复合年增长率成长。该市场的主要驱动因素是全球前列腺癌发病率不断上升、意识和早期筛检计划的提高以及对非侵入性和准确诊断工具的需求不断增长。全球前列腺癌抗原 3 检测市场的未来前景广阔，医院和专科诊所市场充满机会。

前列腺癌抗原3检测按细分市场预测

本研究按类型、应用和地区对全球前列腺癌抗原 3 测试市场进行了预测。

前列腺癌抗原 3 测试市场洞察

Lucintel 预测 RT-PCR 将经历最高的成长。

在这个市场中，医院预计将呈现更高的成长。

亚太地区预计成长最快。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球前列腺癌抗原3检测市场预计将以7.7%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 该市场的主要驱动力是全球前列腺癌发病率不断上升、意识和早期筛检计划的提高以及对非侵入性和准确诊断工具的需求不断增长。

Q3.市场的主要细分市场是：

A3. 前列腺癌抗原3检测市场前景广阔，医院和专科诊所市场充满机会。

Q4.市场的主要企业是：

A4. 摄护腺癌抗原3检测的主要企业如下：

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher

Q5.未来最大的细分市场是什么？

A5.Lucintel 预测 RT-PCR 将经历最高的成长。

Q6.未来五年预计哪些地区的市场成长最大？

A6.亚太地区预计成长最快。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球前列腺癌抗原3检测市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球前列腺癌抗原3检测市场趋势（2018-2023）与预测（2024-2030）
  • 全球前列腺癌抗原3检测市场（按类型）
    • RT-PCR
    • 酵素连结免疫吸附试验
    • 微量中和测定
  • 按应用分列的前列腺癌抗原 3 测试的全球市场
    • 医院
    • 专科诊所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的前列腺癌抗原 3 测试的全球市场
  • 北美前列腺癌抗原3检测市场
  • 欧洲前列腺癌抗原3检测市场
  • 亚太地区前列腺癌抗原3检测市场
  • 其他地区前列腺癌抗原3检测市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球前列腺癌抗原 3 检测市场按类型分類的成长机会
    • 全球前列腺癌抗原 3 检测市场成长机会（按应用）
    • 全球前列腺癌抗原 3 检测市场成长机会（按地区）
  • 全球前列腺癌抗原3检测市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球前列腺癌抗原3检测市场产能
    • 全球前列腺癌抗原3检测市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher
简介目录

Prostate Cancer Antigen 3 Test Trends and Forecast

The future of the global prostate cancer antigen 3 test market looks promising with opportunities in the hospital and specialist clinic markets. The global prostate cancer antigen 3 test market is expected to grow with a CAGR of 7.7% from 2024 to 2030. The major drivers for this market are growing incidence of prostate cancer globally, increasing awareness & early screening programs, and rising demand for non-invasive & accurate diagnostic tools.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Prostate Cancer Antigen 3 Test by Segment

The study includes a forecast for the global prostate cancer antigen 3 test by type, application, and region.

Prostate Cancer Antigen 3 Test Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • RT-PCR
  • ELISA Test
  • Micro-Neutralization Assays

Prostate Cancer Antigen 3 Test Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital
  • Specialist Clinic
  • Others

Prostate Cancer Antigen 3 Test Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Prostate Cancer Antigen 3 Test Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies prostate cancer antigen 3 test companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prostate cancer antigen 3 test companies profiled in this report include-

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher

Prostate Cancer Antigen 3 Test Market Insights

Lucintel forecasts that RT-PCR is expected to witness the highest growth.

Within this market, hospital is expected to witness higher growth.

APAC is expected to witness the highest growth.

Features of the Global Prostate Cancer Antigen 3 Test Market

Market Size Estimates: Prostate cancer antigen 3 test market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Prostate cancer antigen 3 test market size by type, application, and region in terms of value ($B).

Regional Analysis: Prostate cancer antigen 3 test market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the prostate cancer antigen 3 test market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prostate cancer antigen 3 test market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for prostate cancer antigen 3 test market?

Answer: The global prostate cancer antigen 3 test market is expected to grow with a CAGR of 7.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the prostate cancer antigen 3 test market?

Answer: The major drivers for this market are growing incidence of prostate cancer globally, increasing awareness & early screening programs, and rising demand for non-invasive & accurate diagnostic tools.

Q3. What are the major segments for prostate cancer antigen 3 test market?

Answer: The future of the prostate cancer antigen 3 test market looks promising with opportunities in the hospital and specialist clinic markets.

Q4. Who are the key prostate cancer antigen 3 test market companies?

Answer: Some of the key prostate cancer antigen 3 test companies are as follows:

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher

Q5. Which prostate cancer antigen 3 test market segment will be the largest in future?

Answer: Lucintel forecasts that RT-PCR is expected to witness the highest growth.

Q6. In prostate cancer antigen 3 test market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness the highest growth.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the prostate cancer antigen 3 test market by type (RT-PCR, ELISA test, and micro-neutralization assays), application (hospital, specialist clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Prostate Cancer Antigen 3 Test Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Prostate Cancer Antigen 3 Test Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Prostate Cancer Antigen 3 Test Market by Type
    • 3.3.1: RT-PCR
    • 3.3.2: ELISA Test
    • 3.3.3: Micro-Neutralization Assays
  • 3.4: Global Prostate Cancer Antigen 3 Test Market by Application
    • 3.4.1: Hospital
    • 3.4.2: Specialist Clinic
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Prostate Cancer Antigen 3 Test Market by Region
  • 4.2: North American Prostate Cancer Antigen 3 Test Market
    • 4.2.1: North American Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.2.2: North American Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others
  • 4.3: European Prostate Cancer Antigen 3 Test Market
    • 4.3.1: European Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.3.2: European Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others
  • 4.4: APAC Prostate Cancer Antigen 3 Test Market
    • 4.4.1: APAC Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.4.2: APAC Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others
  • 4.5: ROW Prostate Cancer Antigen 3 Test Market
    • 4.5.1: ROW Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.5.2: ROW Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Prostate Cancer Antigen 3 Test Market by Type
    • 6.1.2: Growth Opportunities for the Global Prostate Cancer Antigen 3 Test Market by Application
    • 6.1.3: Growth Opportunities for the Global Prostate Cancer Antigen 3 Test Market by Region
  • 6.2: Emerging Trends in the Global Prostate Cancer Antigen 3 Test Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Prostate Cancer Antigen 3 Test Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Prostate Cancer Antigen 3 Test Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Mdxhealth
  • 7.2: Myriad Genetics
  • 7.3: Abbott
  • 7.4: F. Hoffmann-La Roche Ltd
  • 7.5: Siemens
  • 7.6: OPKO Health
  • 7.7: Genomic Health
  • 7.8: BD
  • 7.9: Agilent Technologies
  • 7.10: Danaher